

BERGENBIO HOSTING VIRTUAL R&D DAY

Agenda

(times in CET)

13:00 **Introduction** - Richard Godfrey, Chief Executive Officer, BerGenBio

Presentations from independent AXL experts, followed by Q&A sessions led by Jim Lorens, Chief Scientific Officer and Hani Gabra, Chief Medical Officer at BerGenBio

13:10 ***AXL in AML/MDS*** – Professor Sonja Loges, Director, Department of Personalised Oncology, University Hospital Mannheim and Division of Personalised Medical Oncology, German Cancer Research Center - DKFZ (Heidelberg, Germany)

13:40 ***AXL in lung cancer*** – Dr Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust (Manchester, UK)

14:10 ***AXL and viruses/COVID-19*** – Professor Wendy Maury, Professor of Microbiology and Immunology, University of Iowa (Iowa City, USA)

14:40 ***AXL in fibrosis/IPF*** – Professor Cory Hogaboam, Professor of Medicine, Cedars-Sinai Medical Center (Los Angeles, USA)

15:10 **Bemcentinib clinical development plan** – Hani Gabra, Chief Medical Officer, BerGenBio

15:25 **Concluding remarks** – Richard Godfrey, Chief Executive Officer, BerGenBio